Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203017 | 0.89 | HTR6 (0.77) | HTR6HTR7 | |
| SCHEMBL6698337 | 0.89 | HTR6 (0.77) | HTR6 | |
| SCHEMBL5201153 | 0.88 | HTR6 (0.69) | HTR6 | |
| Hydrochloric Acid SCHEMBL5201686 | 0.88 | HTR6 (0.76) | HTR6HTR7 | |
| SCHEMBL5202224 | 0.86 | HTR6 (0.69) | HTR6HTR7 | |
| SCHEMBL6698850 | 0.84 | HTR6 (0.63) | HTR6HTR7 | |
| SCHEMBL5201073 | 0.83 | HTR6 (0.78) | HTR6 | |
| SCHEMBL5203694 | 0.83 | HTR6 (0.85) | HTR6 | |
| SCHEMBL1136470 | 0.82 | HTR6 (1.00) | HTR6 | |
| SCHEMBL5201224 | 0.81 | HTR6 (0.68) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401813-B1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | claimed |
| US-20040242589-A1 | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | SMITHKLINE BEECHAM PLC (GB) | 2004-12-02 | — | — | US | claimed |
| US-6787535-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-07 | — | — | US | claimed |
| EP-1401813-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | claimed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | claimed |
| WO-2002098857-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | claimed |
| EP-1401813-B1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| US-20050171118-A1 | New indole derivatives with 5-HT6 receptor affinity | BEARD COLIN C (US) | 2005-08-04 | — | — | US | disclosed |
| US-20040248902-A1 | New indole derivatives with 5-HT6 receptor affinity | BEARD COLIN CHARLES (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040242589-A1 | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | SMITHKLINE BEECHAM PLC (GB) | 2004-12-02 | — | — | US | disclosed |
| US-6787535-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-07 | — | — | US | disclosed |
| EP-1414442-A1 | 3-ARYLSULFONYL-7-PIPERAZINYL- INDOLES, -BENZOFURANS AND -BENZOTHIOPHENES WITH 5-HT6 RECEPTOR AFFINITY FOR TREATING CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | disclosed |
| WO-2003013510-A1 | 3-ARYLSULFONYL-7-PIPERAZINYL- INDOLES, -BENZOFURANS AND -BENZOTHIOPHENES WITH 5-HT6 RECEPTOR AFFINITY FOR TREATING CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242589-A1 | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | HTR6, HTR7, HTR1A | HTR6 1/4885HTR7 2/4885 |
| US-20040248902-A1 | New indole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885HTR7 3/4885 |
| US-20050171118-A1 | New indole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885HTR7 3/4885 |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885HTR7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.